Juno Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Juno Therapeutics Inc.
Uncertainty Clouds Pharma Patent Validity As SCOTUS Ruminates On Amgen Case
The pharma and biotech industry is waiting with bated breath for the decision from the US Supreme Court over a contentious case involving Amgen. The result of the SCOTUS decision could have a huge impact on drugmakers’ profits, commercial strategy, and industry innovation.
Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
Will Genus Claims Be Resuscitated? Supreme Court To Decide In Amgen PCSK9 Patent Dispute
High court will consider the standard for determining if a patent covering a group of related chemicals is enabled in Amgen v. Sanofi. It denies Juno petition seeking review of standard for written description of an invention in CAR T-cell patent suit against Kite.
US Supreme Court Preview: ‘Skinny’ Labels, FTC, And FCA – But No Tecfidera As Biogen Loses Bid
Teva’s carve-out fight with GSK over generic Coreg will see the Solicitor General weigh in. Amgen and Juno’s patent petitions remain pending, and the high court stays a Federal Circuit decision invalidating Novartis’ Gilenya patent.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- AbVitro, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- RedoxTherapies, Inc.
- X-BODY, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.